Media headlines about Amgen (NASDAQ:AMGN) have been trending positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amgen earned a news sentiment score of 0.35 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 45.5478490563898 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:
- Amgen to Support FDA Approval for Biocartis Cancer Test (sfvbj.com)
- Amgen’s PCSK9 Inhibitor Gets FDA Nod for Stroke Prevention (finance.yahoo.com)
- Amgen, Inc. breached its 50 day moving average in a Bullish Manner : AMGN-US : December 5, 2017 (finance.yahoo.com)
- Intraday Trade Strategies in Focus: Amgen Inc (NASDAQ: AMGN) – Alpha Beta Stock (alphabetastock.com)
- Stocks Messing With The Heads Of Investors: SRC Energy Inc. (SRCI), Amgen Inc. (AMGN) – Market Movers (financialqz.com)
Several brokerages have weighed in on AMGN. Cann reissued a “buy” rating and set a $205.00 price objective on shares of Amgen in a report on Thursday, November 30th. Oppenheimer reissued a “buy” rating and set a $205.00 price objective on shares of Amgen in a report on Thursday, November 30th. BMO Capital Markets reissued a “hold” rating and set a $199.00 price objective on shares of Amgen in a report on Monday, September 25th. BidaskClub raised shares of Amgen from a “strong sell” rating to a “sell” rating in a report on Saturday. Finally, Credit Suisse Group reissued a “neutral” rating and set a $186.00 price objective (up from $177.00) on shares of Amgen in a report on Friday, September 29th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Amgen presently has an average rating of “Hold” and a consensus target price of $190.22.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The company had revenue of $5.77 billion for the quarter, compared to the consensus estimate of $5.75 billion. During the same period last year, the firm posted $3.02 EPS. The company’s revenue for the quarter was down .7% on a year-over-year basis. equities analysts expect that Amgen will post 12.66 EPS for the current year.
Amgen declared that its board has initiated a share buyback program on Wednesday, October 25th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board believes its stock is undervalued.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Friday, November 17th will be given a $1.15 dividend. The ex-dividend date of this dividend is Thursday, November 16th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.57%. Amgen’s payout ratio is currently 41.55%.
In related news, Director Carbonnel Francois De sold 4,000 shares of Amgen stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total value of $694,440.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $171.58, for a total transaction of $261,659.50. Following the completion of the sale, the executive vice president now owns 57,631 shares in the company, valued at $9,888,326.98. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 7,050 shares of company stock worth $1,239,673. Insiders own 0.19% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.